Key Drivers
- Gross margin
- FCF pressure
- SBC dilution
AIAI Summary
GoodRx should be viewed as a potential re-rating story driven by Pharma Direct, employer, and manufacturer access programs, but the investment case remains contingent on proving these new growth layers can offset declining legacy coupon revenue and restore consistent free cash flow before the market fully trusts the pivot.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross margin
- •FCF pressure
- •SBC dilution
GDRX still shows strong core economics and a reasonable valuation, but weaker recent cash flow, rising leverage, and heavy stock-based compensation temper the investment case.
Price Behavior
Key Price Behavior Insights:
- •Higher Base
- •Momentum Fade
- •Support Test
Over the last month, GDRX still shows a mildly constructive trend, but the surge to $2.92 has faded into a series of lower closes, putting the $2.28–$2.32 support and $2.55–$2.61 resistance in focus.
Sharp surge to $2.92 on 2026-05-08, followed by a quick pullback and lower closes
Sentiment & News
Key News Insights:
- •In-line Q1
- •Ozempic pricing
- •Access expansion
GoodRx posted in-line Q1 results with solid profitability and expanded its prescription-savings offering by adding self-pay Ozempic pricing, reinforcing its access-focused growth strategy.
The news should be modestly supportive for GoodRx by highlighting stable execution and continued demand for its drug-savings platform
Similar Companies in Healthcare
Other companies in the same sector with AI ratings